ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 宜明昂科生物醫藥技術（上海）股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：1541） 自願公告 由本集團獨立研發的IMM0306是一種靶向分化簇47(CD47)及分化簇20(CD20) 的雙特異性分子，是全球首個進入臨床階段的CD47和CD20雙靶向雙特異性 分子。IMM0306透過抑制CD47-SIRPα相互作用來阻斷「別吃我」訊號，增強Fc- FcγRIIa和Fc-FcγRIIIa相互作用來激活巨噬細胞和NK細胞，並優先結合CD20而 非CD47，以有效消除惡性B細胞，同時將毒性降至最低，從而可改善治療效果。 – 1 – 截至本公告日期，本集團擁有IMM0306的全球知識產權及商業化權利。 藥品審評中心批准IMM0306治療復發╱難治性濾泡性淋巴瘤的III期 臨床研究方案 本公告由宜明昂 ...

Core Viewpoint - The company has announced the cash redemption of its financial products held with Huatai Financial, totaling approximately HKD 93.33 million, and plans to reinvest in new financial products worth HKD 120 million [1] Group 1: Redemption Details - The company notified Huatai Financial on November 20, 2025, regarding the cash redemption of HKD 49.6033 million for the first redemption and HKD 43.72 million for the second redemption [1] - The estimated income from these redemptions is approximately HKD 3.46 million and HKD 1.27 million, respectively, representing the unaudited interest income generated from the redemptions [1] - After the redemption, the company will no longer hold any outstanding financial products from Huatai Financial [1] Group 2: New Investment - On the same date, the company agreed to subscribe to a new financial product from Huatai Financial, amounting to HKD 120 million [1] - The funding for this subscription will be sourced from the company's internal cash reserves [1]

Core Viewpoint - The company has announced the cash redemption of its financial products held with Huatai Financial, totaling approximately HKD 93.33 million, and plans to reinvest in new financial products worth HKD 120 million [1] Group 1: Redemption Details - The company notified Huatai Financial on November 20, 2025, regarding the cash redemption of HKD 49.6033 million for the first redemption and HKD 43.72 million for the second redemption [1] - The estimated income from the redemptions is approximately HKD 3.46 million and HKD 1.27 million, respectively, representing the unaudited interest income generated from these redemptions [1] Group 2: Future Investments - Following the redemption, the company will no longer hold any outstanding financial products from Huatai Financial [1] - On the same date, the company agreed to subscribe to a new financial product from Huatai Financial, amounting to HKD 120 million, funded by the company's internal cash reserves [1]

Core Viewpoint - The company, 宜明昂科-B (01541.HK), has announced the redemption of two financial products from 华泰金融, with a total redemption amount of 9.332 million HKD and estimated returns of approximately 473,000 HKD [1] Group 1: Financial Products - The company has subscribed to two financial products from 华泰金融, amounting to 49.6 million HKD for the "2023 Deferred Product" and 43.72 million HKD for the "2024 Product" [1] - The board has notified 华泰金融 on November 20, 2025, for cash redemption of the total amounts held in the financial products, with estimated returns of about 346,000 HKD and 127,000 HKD respectively [1] - After the redemption, the group will no longer hold any outstanding financial products from 华泰金融 [1] Group 2: Future Investments - On the same date, the company agreed to subscribe to a new financial product from 华泰金融 for an amount of 120 million HKD, funded by the group's internal cash reserves [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 （股份代號：1541） 須予披露交易 贖回及認購理財產品 茲提述本公司日期為2025年3月25日及2025年5月27日的公告，內容有關向華 泰金融認購兩項理財產品，金額分別為49,603,273港元（「2023年延期產品」） 及43,720,000港元（「2024年產品」）（「華泰贖回產品」）。 贖回及認購理財產品 董事會宣佈，本公司已於 2025 年 11 月 20 日通知華泰金融，以現金贖回 49,603,273港元（「首次贖回」）及43,720,000港元（「第二次贖回」）的華泰贖回產 品，即其當時分別持有的全部華泰贖回產品，估計收益分別約為3,460,000港 元及1,270,000港元（統稱「贖回事項」）（即贖回事項分別產生的未經審計利息 收入）。於贖回事項後，本集團將不再持有華泰金融任何尚未到期理財產品。 此外，於2025年11月20日，本公司同意向華泰金融認購金額為120,000,000港 ...

宜明昂科生物醫藥技術（上海）股份有限公司 章程 | 第一章 | 總則 | 3 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 4 | | 第三章 | 股份 | 5 | | 第一節 | 股份發行 | 5 | | 第二節 | 股份增減和回購 | 10 | | 第三節 | 股份轉讓 | 12 | | 第四章 | 股東和股東大會 | 14 | | 第一節 | 股東 | 14 | | 第二節 | 股東大會的一般規定 | 21 | | 第三節 | 股東大會的召集 | 25 | | 第四節 | 股東大會的提案與通知 | 27 | | 第五節 | 股東大會的召開 | 30 | | 第六節 | 股東大會的表決和決議 | 34 | | 第五章 | 董事會 | 40 | | 第一節 | 董事 | 40 | | 第二節 | 董事會 | 44 | | 第三節 | 董事會專門委員會 | 49 | | 第六章 | 總經理及其他高級管理人員 | 50 | | 第七章 | 監事會 | 52 | | 第一節 | 監事 | 52 | | 第二節 | 監事會 | 53 | | 第八章 | 財務會計制度、利潤分配和審計 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 倚賴該等內容而引致的任何損失承擔任何責任。 ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 宜明昂科生物醫藥技術（上海）股份有限公司 本公告乃根據香港聯合交易所有限公司證券上市規則第13.51(1)條而刊發。 茲提述宜明昂科生物醫藥技術（上海）股份有限公司（「本公司」）日期為2024年11 月21日及11月28日以及2025年10月9日及10月16日的公告（「該等公告」），內容有 關根據一般授權配售本公司新H股（「H股」）（「配售事項」）及其完成。於配售事 項完成後，本公司已發行股份（「股份」）總數由407,307,695股增加至431,507,695 股及已發行H股總數由396,277,305股H股增加至420,477,305股H股。為反映本公司 註冊資本的有關變更，本公司已對其組織章程細則（「章程」）作出相應修訂（「該 等修訂」），詳情如下。 | 細則序號 | 作出該等修訂前 | | | | | | ...

Core Viewpoint - The company, Yiming Anke-B (01541), announced that its Executive Director, CEO, and Chairman, Dr. Tian Wenzhi, purchased a total of 50,000 H-shares in the open market at an average price of approximately HKD 7.95 per share, representing about 0.01% of the company's total issued shares [1] Summary by Relevant Sections - **Share Purchase Details** - Dr. Tian Wenzhi acquired 50,000 H-shares at an average price of approximately HKD 7.95 per share [1] - Following the purchase, Dr. Tian holds a total of 116 million shares, which constitutes 26.90% of the company's total issued share capital as of the announcement date [1] - **Management's Confidence** - Dr. Tian expressed confidence in the overall development prospects and potential growth of the company [1] - He indicated that he does not rule out the possibility of further increasing his shareholding in the company at an appropriate time, in compliance with applicable laws and regulations [1]

Core Viewpoint - The company announced that its Executive Director, CEO, and Chairman, Dr. Tian Wenzhi, purchased a total of 50,000 H-shares in the open market at an average price of approximately HKD 7.95 per share, representing about 0.01% of the company's total issued shares [1] Group 1 - Following the purchase, Dr. Tian holds a total of 116 million shares, which accounts for 26.90% of the company's total issued share capital as of the announcement date [1] - Dr. Tian expressed confidence in the overall development prospects and potential growth of the group [1] - Dr. Tian does not rule out the possibility of further increasing his shareholding in the company at an appropriate time, in compliance with applicable laws and regulations [1]

Group 1 - The company announced that Tian Wenzhi purchased a total of 50,000 shares of the company's H-shares on the open market at an average price of approximately 7.9500 HKD per share, representing about 0.01% of the company's total issued shares [1] - Following the purchase, Tian Wenzhi holds a total of 116,084,090 shares, which accounts for 26.90% of the company's total issued share capital as of the date of the announcement [1]